3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
33
Lung Neoplasms
13
Breast Neoplasms
12
Colorectal Neoplasms
11
Ovarian Neoplasms
10
Recurrence
9
Neoplasms
9
Small Cell Lung Carcinoma
8
Neoplasm Metastasis
8
Head and Neck Neoplasms
8
Urinary Bladder Neoplasms
7
Squamous Cell Carcinoma of Head and Neck
7
Lymphoma, Large B-Cell, Diffuse
7
Prostatic Neoplasms
6
Carcinoma, Hepatocellular
6
Triple Negative Breast Neoplasms
5
Pancreatic Neoplasms
5
Diabetes Mellitus, Insulin-Dependent, 12
5
Carcinoma
5
Multiple Myeloma
4
Lymphoma, Follicular
4
Cholangiocarcinoma
4
Uterine Cervical Neoplasms
3
Recurrent Squamous Cell Lung Carcinoma
3
Oropharyngeal Neoplasms
3
Mouth Neoplasms
3
Mesothelioma
3
Lymphoma, Non-Hodgkin
3
Lymphoma
3
Kidney Neoplasms
3
Interventions
Gemcitabine
7
Cisplatin
5
Ramucirumab
3
Platinum
3
Paclitaxel
3
Docetaxel
3
1,2-diaminocyclohexaneplatinum II citrate
3
pembrolizumab
2
Carboplatin
2
rucaparib
1
pegfilgrastim
1
pazopanib
1
eribulin
1
enzalutamide
1
enfortumab vedotin
1
dehydroftorafur
1
cabozantinib
1
avelumab
1
atezolizumab
1
aflibercept
1
Taxes
1
Surgical Procedures, Operative
1
Sunitinib
1
Standard of Care
1
Specimen Handling
1
Sorafenib
1
Radiotherapy
1
Radiation
1
N-(3-aminopropyl)-N-(1-(5-benzyl-3-methyl-4-oxo-(1,2)thiazolo(5,4-d)pyrimidin-6-yl)-2-methylpropyl)-4-methylbenzamide
1
Mitozytrex
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Urethral Neoplasms
×
durvalumab
×
Clear all
No trials found.